Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of decitabine for the front-line treatment of older patients with acute myeloid leukemia

X
Trial Profile

A phase II study of decitabine for the front-line treatment of older patients with acute myeloid leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 16 Mar 2019 Results assessing population pharmacokinetic analysis from 71 adult and 28 pediatric subjects of decitabine in pediatric patients with acute myeloid leukemia presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 11 Dec 2018 A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies (DACO-018, DACO-017, DACO-020, DACO-016, E7373-A001-101, E7373-G000-202 and DACOGENAML2004 trial); results published in the Journal of Clinical Pharmacology
    • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top